Advaxis, Inc. Risk Report

🛡️ Financial & Liquidity

Advaxis, Inc. has experienced significant financial changes and acquisitions in recent years. OS Therapies' acquisition of key assets from Advaxis, completed in 2025, marks a pivotal rearrangement of Advaxis' financial landscape. Previously in 2023, Advaxis merged with Ayala Pharmaceuticals, further solidifying their strategic position in the market. The volatility of Advaxis' financial operations has been evident through these major transactions, reflecting on their adaptive business strategy amid financial risks.

• OS Therapies completed the acquisition of Advaxis immunotherapies clinical, pre-clinical, and IP assets from Ayala Pharmaceuticals 🗓 April 9, 2025.
• Advaxis and Ayala Pharmaceuticals completed their merger 🗓 January 19, 2023.
• Ayala Pharmaceuticals and Advaxis agreed to combine, with expectations of uplisting on Nasdaq 🗓 October 19, 2022.
• Advaxis Inc. shares surged past their previous 52-week high, indicating market movement 🗓 January 16, 2022.

⚖️ Legal & Regulatory

There have been legal developments surrounding Advaxis, mainly focusing on their merger activities. The merging and acquisition processes with Ayala Pharmaceuticals have positioned the company within a complex regulatory landscape, requiring compliance with legal frameworks. This highlights their ability to manage legal challenges inherent in significant corporate restructurings.

• Morgan Lewis advised Advaxis in the Ayala Pharmaceuticals merger 🗓 October 19, 2022.
• Ayala Pharmaceuticals announced the closing of a merger with Biosight, a move impacting Advaxis 🗓 October 19, 2023.

👥 Labor & Workforce

Operational strategies within Advaxis have led to workforce adjustments to align business goals with economic realities. The company's strategic decisions have occasionally impacted their workforce, notably through layoffs linked to business pivots towards their cancer pipeline.

• Advaxis laid off staff as part of a strategy to refocus their cancer pipeline 🗓 June 8, 2018.

📜 Innovation & R&D

Innovation and research continue to be at the forefront of Advaxis' strategic operations, demonstrating a focused effort on advancing their oncological pipeline. Their collaborations and study completions underscore their role in the biotechnology sector, specifically aiming at vaccines and immune therapies as significant innovations.

• Advaxis announced publication of ADXS-PSA data in The Oncologist, reflecting continued innovation in their cancer research 🗓 April 8, 2022.
• Advaxis began a Phase 3 study of its Axal vaccine for advanced cervical cancer 🗓 November 9, 2016.